Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00996918
Registration number
NCT00996918
Ethics application status
Date submitted
14/10/2009
Date registered
16/10/2009
Date last updated
1/01/2014
Titles & IDs
Public title
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
Query!
Scientific title
A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000
Query!
Secondary ID [1]
0
0
B2521003
Query!
Secondary ID [2]
0
0
3133K1-3002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alzheimer Disease
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Alzheimer's disease
Query!
Neurological
0
0
0
0
Query!
Dementias
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Bapineuzumab 0.5 mg/kg
Treatment: Drugs - Bapineuzumab 1.0 m/kg
Experimental: Bapineuzumab 0.5 mg/kg - bapineuzumab
Experimental: Bapineuzumab 1.0 m/kg - bapineuzumab
Treatment: Drugs: Bapineuzumab 0.5 mg/kg
Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
Treatment: Drugs: Bapineuzumab 1.0 m/kg
I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants Reporting a Serious Adverse Event.
Query!
Assessment method [1]
0
0
Safety was measured according to standard adverse event collection as described in the Adverse Event Section of the Results. Complete tables of events are provided there.
Query!
Timepoint [1]
0
0
Up to Week 195
Query!
Secondary outcome [1]
0
0
Change From Base Study Baseline in Alzheimer's Disease Assesment Scale-Cognitive Subscale (ADAS-Cog/11) at Weeks 13, 26, 39, 52 and 78.
Query!
Assessment method [1]
0
0
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Query!
Timepoint [1]
0
0
Weeks 13, 26, 39, 52 and 78
Query!
Secondary outcome [2]
0
0
Change From Extension Study Baseline in ADAS-Cog/11 at Weeks 13, 26, 39, 52 and 78.
Query!
Assessment method [2]
0
0
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Query!
Timepoint [2]
0
0
Weeks 13, 26, 39, 52 and 78
Query!
Secondary outcome [3]
0
0
Change From Base Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.
Query!
Assessment method [3]
0
0
The DAD measures instrumental and basic activities of daily living in participants with Alzheimer's Disease (AD). The DAD is administered to the participants'caregiver in the form of an interview. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced by the participant. This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores indicate better function; a positive change from baseline indicates an improvement
Query!
Timepoint [3]
0
0
Weeks 13, 26, 39, 52 and 78
Query!
Secondary outcome [4]
0
0
Change From Extension Study Baseline in DAD Score at Weeks 13, 26, 39, 52 and 78
Query!
Assessment method [4]
0
0
The DAD measures instrumental and basic activities of daily living in participants with AD. The DAD is administered to the participants'caregiver in the form of an interview. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced by the participant. This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores indicate better function; a positive change from baseline indicates an improvement
Query!
Timepoint [4]
0
0
Weeks 13, 26, 39, 52 and 78
Query!
Secondary outcome [5]
0
0
Change From Base Study Baseline in Neuropsychiatric Inventory (NPI) Score at Weeks 26, 52 and 78.
Query!
Assessment method [5]
0
0
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. Severity (1=Mild to 3=Severe), frequency (1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score (range 0-144); higher score=greater behavioral disturbances; negative change score from baseline=improvement.
Query!
Timepoint [5]
0
0
Weeks 26, 52 and 78
Query!
Secondary outcome [6]
0
0
Change From Extension Study Baseline in NPI Score at Weeks 26, 52 and 78.
Query!
Assessment method [6]
0
0
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, night-time behavior. Severity (1=Mild to 3=Severe), frequency (1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score(range 0-144); higher score=greater behavioral disturbances; negative change score from baseline=improvement.
Query!
Timepoint [6]
0
0
Weeks 26, 52 and 78
Query!
Secondary outcome [7]
0
0
Change From Base Study Baseline in Mini-mental State Examination (MMSE) Score at Weeks 6, 19, 32, 45 and 78.
Query!
Assessment method [7]
0
0
MMSE measured general cognitive functioning: orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons. Total score derived from sub-scores; total ranged from 0 to 30, higher score indicates better cognitive state.
Query!
Timepoint [7]
0
0
Weeks 6, 19, 32, 45 and 78
Query!
Secondary outcome [8]
0
0
Change From Extension Study Baseline in MMSE Score at Weeks 6, 19, 32, 45 and 78.
Query!
Assessment method [8]
0
0
MMSE measured general cognitive functioning: orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons. Total score derived from sub-scores; total ranged from 0 to 30, higher score indicates better cognitive state
Query!
Timepoint [8]
0
0
Weeks 6, 19, 32, 45 and 78
Query!
Eligibility
Key inclusion criteria
- Subject has completed study 3133K1-3000 and brain magnetic resonance imaging (MRI)
scan consistent with the diagnosis of Alzheimer Disease
- Mini-Mental Status Examination (MMSE) >=10 at screening
- Caregiver able to attend all clinic visits with subject
Query!
Minimum age
51
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Any medical or psychiatric contraindication or clinically significant abnormality
that, in the investigator's judgment, will substantially increase the risk associated
with the subject's participation in and completion of the study or could preclude the
evaluation of the subject's response.
- Any significant brain MRI abnormality.
- Use of any investigational drugs or devices, other than bapineuzumab within the last
60 days prior to screening
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
198
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Pfizer Investigational Site - Hornsby
Query!
Recruitment hospital [2]
0
0
Pfizer Investigational Site - Adelaide
Query!
Recruitment hospital [3]
0
0
Pfizer Investigational Site - Woodville South
Query!
Recruitment hospital [4]
0
0
Pfizer Investigational Site - Heidelberg Heights
Query!
Recruitment hospital [5]
0
0
Pfizer Investigational Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2077 - Hornsby
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [4]
0
0
3081 - Heidelberg Heights
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Antwerpen
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Brussels
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Edegem
Query!
Country [4]
0
0
Chile
Query!
State/province [4]
0
0
Santiago
Query!
Country [5]
0
0
Finland
Query!
State/province [5]
0
0
Kuopio
Query!
Country [6]
0
0
Finland
Query!
State/province [6]
0
0
Turku
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Caen
Query!
Country [8]
0
0
France
Query!
State/province [8]
0
0
Dijon
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Lille
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Marseille
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Montpellier
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Nantes - Saint Herblain
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Nice
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Paris
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Poitiers
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Rennes
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Rouen
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Toulouse
Query!
Country [19]
0
0
Italy
Query!
State/province [19]
0
0
Milano
Query!
Country [20]
0
0
Italy
Query!
State/province [20]
0
0
Roma
Query!
Country [21]
0
0
Japan
Query!
State/province [21]
0
0
Aichi
Query!
Country [22]
0
0
Japan
Query!
State/province [22]
0
0
Chiba
Query!
Country [23]
0
0
Japan
Query!
State/province [23]
0
0
Fukuoka
Query!
Country [24]
0
0
Japan
Query!
State/province [24]
0
0
Hiroshima
Query!
Country [25]
0
0
Japan
Query!
State/province [25]
0
0
Hyogo
Query!
Country [26]
0
0
Japan
Query!
State/province [26]
0
0
Kagawa
Query!
Country [27]
0
0
Japan
Query!
State/province [27]
0
0
Kanagawa
Query!
Country [28]
0
0
Japan
Query!
State/province [28]
0
0
Kyoto
Query!
Country [29]
0
0
Japan
Query!
State/province [29]
0
0
Nagano
Query!
Country [30]
0
0
Japan
Query!
State/province [30]
0
0
Okayama
Query!
Country [31]
0
0
Japan
Query!
State/province [31]
0
0
Osaka
Query!
Country [32]
0
0
Japan
Query!
State/province [32]
0
0
Shizuoka
Query!
Country [33]
0
0
Japan
Query!
State/province [33]
0
0
Tokyo
Query!
Country [34]
0
0
Netherlands
Query!
State/province [34]
0
0
's-Hertogenbosch
Query!
Country [35]
0
0
Netherlands
Query!
State/province [35]
0
0
Leeuwarden
Query!
Country [36]
0
0
New Zealand
Query!
State/province [36]
0
0
NZ
Query!
Country [37]
0
0
Poland
Query!
State/province [37]
0
0
Bydgoszcz
Query!
Country [38]
0
0
Poland
Query!
State/province [38]
0
0
Krakow
Query!
Country [39]
0
0
Poland
Query!
State/province [39]
0
0
Poznan
Query!
Country [40]
0
0
Poland
Query!
State/province [40]
0
0
Warszawa
Query!
Country [41]
0
0
Portugal
Query!
State/province [41]
0
0
Amadora
Query!
Country [42]
0
0
Portugal
Query!
State/province [42]
0
0
Coimbra
Query!
Country [43]
0
0
Portugal
Query!
State/province [43]
0
0
Lisboa
Query!
Country [44]
0
0
Slovakia
Query!
State/province [44]
0
0
Bratislava
Query!
Country [45]
0
0
Slovakia
Query!
State/province [45]
0
0
Rimavska Sobota
Query!
Country [46]
0
0
South Africa
Query!
State/province [46]
0
0
Gauteng
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Alicante
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Barcelona
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Caceres
Query!
Country [50]
0
0
Spain
Query!
State/province [50]
0
0
Islas Baleares
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Burgos
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Madrid
Query!
Country [53]
0
0
Sweden
Query!
State/province [53]
0
0
Malmo
Query!
Country [54]
0
0
Switzerland
Query!
State/province [54]
0
0
BS
Query!
Country [55]
0
0
United Kingdom
Query!
State/province [55]
0
0
Brighton
Query!
Country [56]
0
0
United Kingdom
Query!
State/province [56]
0
0
Glasgow
Query!
Country [57]
0
0
United Kingdom
Query!
State/province [57]
0
0
London
Query!
Country [58]
0
0
United Kingdom
Query!
State/province [58]
0
0
Newcastle upon Tyne
Query!
Country [59]
0
0
United Kingdom
Query!
State/province [59]
0
0
Penarth
Query!
Country [60]
0
0
United Kingdom
Query!
State/province [60]
0
0
Sheffield
Query!
Country [61]
0
0
United Kingdom
Query!
State/province [61]
0
0
Swindon
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab
in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810). Over
250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each
subject's participation will last approximately 4 years.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00996918
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00996918
Download to PDF